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Abstract
Fucan is a term used to denote a family of sulfated L-fucose-rich
polysaccharides which are present in the extracellular matrix of brown
seaweed and in the egg jelly coat of sea urchins. Plant fucans have
several biological activities, including anticoagulant and antithrom-
botic, related to the structural and chemical composition of polysac-
charides. We have extracted sulfated polysaccharides from the brown
seaweed Dictyota menstrualis by proteolytic digestion, followed by
separation into 5 fractions by sequential acetone precipitation. Gel
electrophoresis using 0.05 M 1,3-diaminopropane-acetate buffer, pH
9.0, stained with 0.1% toluidine blue, showed the presence of sulfated
polysaccharides in all fractions. The chemical analyses demonstrated
that all fractions are composed mainly of fucose, xylose, galactose,
uronic acid, and sulfate. The anticoagulant activity of these heterofucans
was determined by activated partial thromboplastin time (APTT)
using citrate normal human plasma. Only the fucans F1.0v and F1.5v
showed anticoagulant activity. To prolong the coagulation time to
double the baseline value in the APTT, the required concentration of
fucan F1.0v (20 µg/ml) was only 4.88-fold higher than that of the low
molecular weight heparin Clexane® (4.1 µg/ml), whereas 80 µg/ml
fucan 1.5 was needed to obtain the same effect. For both fucans this
effect was abolished by desulfation. These polymers are composed of
fucose, xylose, uronic acid, galactose, and sulfate at molar ratios of
1.0:0.8:0.7:0.8:0.4 and 1.0:0.3:0.4:1.5:1.3, respectively. This is the
fist report indicating the presence of a heterofucan with higher antico-
agulant activity from brown seaweed.
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The leading causes of death in the United
States are diseases of the heart and blood
vessels, with the consequent occurrence of
thrombosis. The death rate due to thrombo-
sis is almost twice the rate due to cancer,
which is the second cause of death in the US
(1).
An ideal anticoagulant should have the
following features: effectiveness, safety and
lack of serious toxicity, a mechanism of ac-
tion independent of the metabolic pathway
of vitamin K (metabolism independent of the
cytochrome p-450 system), a wide therapeu-
tic window, no need for monitoring, oral
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bioavailability (for long-term use), safety
during pregnancy, low cost, and a short half-
life for drugs used in the acute setting of
thrombosis or a long half-life for prophy-
laxis (2). However, the drugs currently used
as anticoagulants have various limitations,
thus being far from ideal. This explains cur-
rent efforts to develop specific and potent
anticoagulant agents. Several compounds
have been shown to be effective in ex vivo or
animal thrombosis models. Among them,
sulfated polysaccharides are the compounds
most extensively studied.
Unfractionated heparins and low molec-
ular weight heparins (LMWH) are the only
sulfated polysaccharides currently used as
anticoagulants. However, heparins have sev-
eral limitations such as dependence on anti-
thrombin for their anticoagulant action, the
need to monitor their effect, lack of general
availability of anti-factor Xa assays, inabil-
ity to bind to and inactivate cell membrane-
and clot-bound thrombin and platelet-bound
factor Xa, potential development of heparin-
induced thrombocytopenia, osteoporotic ef-
fect of long-term use, dose-dependent clear-
ance and lack of a linear dose-response curve,
and lack of oral bioavailability. LMWH have
significantly improved heparin management
since monitoring is not needed in most pa-
tients and the dose response is predictable.
They also cause less osteoporosis than un-
fractionated heparins and involve a reduced
risk of inducing heparin-induced thrombo-
cytopenia. However, several of the above
limitations of heparin continue to limit its
usefulness. However, in the last decade there
was a tremendous increase in the sales of
LMWH, reaching 2.5 billion dollars in 1999
compared to 150 million dollars for unfrac-
tionated heparins (1).
The various limitations of heparin and
LMWH have led to the development of other
sulfated polysaccharides that are more ef-
fective, safer, and easier to use anticoagu-
lants for the short-term treatment of arterial
and venous thromboembolic disorders and
for the long-term prevention of recurrences.
These agents are fucan, pentosan sulfate (3),
galactan, fucosylated chondroitin (4), hepa-
ran sulfate from different sources, and other
sulfated glycosaminoglycans from inverte-
brates (1). Among them, fucans are the sul-
fated polysaccharides from vegetal source
most extensively studied as anticoagulant
compounds (5).
Fucan is a term used to denote a family of
sulfated L-fucose-rich polysaccharides with
extremely variable molecular weights. They
are extracted mainly from the extracellular
matrix of brown seaweed (6) and from the
egg jelly coat of sea urchin (7).
Since the first description of the fucans
isolated from algae, these polysaccharides
have been widely tested for biological activi-
ties in different mammalian systems. Plant
fucans have antiviral (8), anti-adhesion (9),
anticoagulant (10), and anti-inflammatory
activity, as well as antiproliferative and anti-
tumoral properties (5). The structures of these
fucans vary among species and sometimes
among different parts of seaweed (11). Fur-
thermore, in contrast to animal fucans, algal
fucans contain portions of other neutral sug-
ars and uronic acids in addition to sulfate
and fucose. Therefore, each new fucan puri-
fied is a new compound with unique struc-
tural features, thus representing a potential
novel drug.
The structural characteristics of fucans
necessary for all of the biological activities
cited above have not been determined; con-
sequently, the relationships between struc-
ture and biological activities have not been
clearly established. Most of the difficulties
for these studies arise from the fact that these
compounds are highly heterogeneous with
complex NMR spectra with broad signals
that hamper resolution (12). In fact, even
high-field NMR is of limited value for these
plant polysaccharides, and complete descrip-
tions of their structures are not available at
present. However, meaningful structural stud-
ies with NMR are possible with relatively
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low molecular weight fucans (LMWFs) pre-
pared by several methods such as acid hy-
drolysis of high molecular weight fucans
(10) or extracted from brown seaweed (13).
The extraction of LMWFs from brown sea-
weed would be very important to determine
the structure/biological activity relationships
of fucans.
We extracted LMWFs from the brown
seaweed Dictyota menstrualis. Briefly, the
alga was dried and 50 g of dried powder was
suspended with 5 volumes of 0.25 M NaCl
and the pH of the mixture was adjusted to 8.0
with NaOH. Ten milligrams of maxatase, an
alkaline protease from Esporobacillus
(BioBras, MG, Brasil), was then added to
the mixture for proteolytic digestion. After a
24-h incubation at 60ºC with agitation the
mixture was filtered through cheesecloth.
The fractionation of the filtrate by precipita-
tion with acetone was as follows: a 0.5 vol-
ume of ice-cold acetone was added to the
solution which was kept at 4ºC, under gentle
shaking, and the solution was left to stand at
the same temperature for an additional 24 h.
The precipitate formed was collected by cen-
trifugation at 10,000 g for 20 min, dried
under vacuum, resuspended in distilled wa-
ter, and analyzed. Acetone, 1.0, 1.5, 2.0, and
3.0 volumes calculated from the initial solu-
tion, was added to the supernatant and the
operations were repeated as described above.
With this procedure, we obtained five frac-
tions named fractions F0.5v, F1.0v, F1.5v,
F2.0v and F3.0, respectively. For fucan visu-
alization, the fractions were submitted to
agarose gel electrophoresis in 0.05 M 1,3-
diaminopropane-acetate buffer, pH 9.0 (11)
and the gel was dried and stained for 15 min
with 0.1% toluidine blue in acetic acid/etha-
nol/water (0.1:5:4.9, v/v). The gel was then
destained with the same solvent.
The electrophoretic profiles showed the
presence of a polydisperse component in
fraction F1.0v, while the other fractions
showed a single band each (Figure 1). Table
1 shows the molecular weight of the fraction
CS
DS
HS
OR
F0.5v F1.0v F1.5v F2.0v F3.0v P
Figure 1. Diaminopropane acetate electrophoresis of the heterofucan fractions. Five-
milliliter aliquots of the fractions shown were applied to agarose gel (7.5 x 10 cm, 0.2-cm
thick) prepared in 0.05 M 1,3-diaminopropane-acetate buffer, pH 9.0, and subjected to
electrophoresis at 110 V/cm for 60 min. The gels were then maintained in 0.1% cetyltri-
methylammonium bromide for 4 h and dried, and the polysaccharides were stained with
0.1% toluidine blue in a solution containing 50% ethanol and 1% acid acetic in water for 15
min. The gels were then destained with the same solution without toluidine blue. P, 10 µg
each of heparan sulfate (HS), dermatan sulfate (DS), and chondroitin sulfate (CS). F0.5v,
F1.0v, F1.5v, F2.0v, F3.0v = fucans precipitated with 0.5, 1.0, 1.5, 2.0 and 3.0 acetone
volumes. OR = origin.
components, determined by HPLC in 0.2 M
NaCl, 0.5% ethanol, using a GF-250 column
(Asahipak GF series, Asahi Chemical Indus-
try Co., Yakoo, Japan). The column was
calibrated with standard glycosaminoglycans.
The sugar composition of the polymers
was determined by paper chromatography
and by gas-liquid chromatography of alditol
acetate as derivative (13). The polymers are
composed mainly of fucose, galactose, xy-
lose, and uronic acid (Table 1) and are com-
posed of heterofucans with a significant pro-
portion of non-fucose sugar components.
These heterofucans have been described
since 1950 (6) and in some cases galactose
was reported to be a major component
(14,15). Because they have not been fre-
quently described, we decided to analyze the
anticoagulant activity of these LMWFs from
D. menstrualis.
Several homofucans showing anticoagu-
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lant activity have been extracted from differ-
ent brown seaweeds (3). However, there are
only few reports on the anticoagulation mech-
anism of homofucans. In general, the pro-
posed mechanism of action is a predomi-
nantly direct one on antithrombin (throm-
bin-fibrinogen complex) and on heparin co-
factor II-mediated antithrombin activities,
with a minor involvement of antithrombin
III. Their anticoagulant activities depend on
their sulfate content and molecular weight
(10,11,16,17). On the other hand, to the best
of our knowledge, there are no data about the
mechanism of action of heterofucans.
In our case, only fractions F1.0v and
F1.5v obtained from D. menstrualis showed
anticoagulant activity (Table 1). Interestingly,
F1.0v was a more potent anticoagulant than
F1.5v in spite of being less sulfated. There-
fore, the increased anticoagulant activity of
F1.0v is unlike to be merely a charge density
effect. These fucans were desulfated by sol-
volysis in dimethylsulfoxide as previously
described (6) and both heterofucans lost their
anticoagulant activity after desulfation (Table
1).
The anticoagulant activity was determined
by activated partial thromboplastin time
(APTT). This assay was carried out accord-
ing to the manufacturer specification (Labtest,
São Paulo, SP, Brazil) as previously de-
scribed (4). Briefly, citrate normal human
plasma (90 µl) was mixed with 10 µl solu-
tion of F1.0v or F1.5v at different concentra-
tions and incubated for 1 min at 37ºC. Then,
APTT assay reagent (100 µl) was added to
the mixture and incubated for 6 min at 37ºC.
Thereafter, 20 mM CaCl2 (100 µl) was added
and the clotting time was recorded. The time
of control (without fucans) was 36.4 s. To
prolong the coagulation time to double the
baseline value in the APTT, the required
concentration of LMWF F1.0v (20 µg/ml)
was 4.88-fold higher than that of the LMWH
Clexane® (4.1 µg/ml). This was an interest-
ing result, since Millet et al. (18) have shown
that a higher concentration (>50 µg/ml) of an
LMW homofucan was required for an equiva-
lent prolongation of the APTT.
Heterofucans with similar chemical com-
position of F1.0v and F1.5v isolated from
brown algae Spatoglossum schröederi (13)
and Sargassum stenophyllum (15), have shown
very low anticoagulant activity, suggesting that
the anticoagulant heterofucans from D.
menstrualis have distinct structural features.
Table 1. Anticoagulant activity, molecular weight, and composition of the low molecu-
lar weight fucans from Dictyota menstrualis.
Fucans APTT MW Fucose Xylose Uronic acid Galactose SO3Na
F0.5v nd 9,000 1 0.4 0.8 0.8 0.04
F1.0v 20 9,300 1 0.8 0.7 0.8 0.4
F1.5v 80 9,100 1 0.3 0.4 1.5 1.3
F2.0v nd 9,200 1 0.7 0.2 1.2 1.1
F3.0v nd 8,900 1 1.1 0.5 1.0 1.2
DF1.0v nd 8,750 1 0.7 0.7 0.7 0.02
DF1.5v nd 7,200 1 0.3 0.4 1.3 0.3
Heparin 0.6 12,000 - - - - -
Clexane® 4.1 4,500 - - - - -
Data are reported as concentration (µg/ml) required to double APTT compared to
minus fucan control. The standard deviation was 8-12% for three measurements.
Molecular weight (MW) was determined by HPLC using glycosaminoglycans as
standard. APTT = activated partial thromboplastin time; nd = anticoagulant activity not
detected with up to 200 µg/ml; DF1.0v = desulfated F1.0v, and DF1.5v = desulfated
F1.5v. Value determined for the control = 36.4 s.
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